Please provide your email address to receive an email when new articles are posted on . Compared with placebo, most biologic and small molecule therapies correlated with superiority for the induction ...

Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92 Data from the ...

A maintenance program with mirikizumab offered clinical benefit in patients with moderate-to-severe ulcerative colitis who first responded to induction therapy with the drug, according to the phase ...

Credit: Shutterstock. Risankizumab is an interleukin-23 inhibitor. Treatment with risankizumab led to a significant proportion of adults with moderately to severely active ulcerative colitis achieving ...

Please provide your email address to receive an email when new articles are posted on . Significant improvements in clinical remission rates were observed at 12 weeks with risankizumab vs. placebo (20 ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Induction ...

TREMFYA ® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease TREMFYA ® achieved significant rates of ...

After acing a study for the induction treatment of ulcerative colitis, AbbVie’s Skyrizi has snatched another win in a maintenance trial. An approval now looks within reach for 2024. Compared with ...

55.2 percent of induction responder patients treated with STELARAat the start of maintenance were in symptomatic remission approximately four years later (at week 200), 96.4 percent without ...

The lowest effective recommended dosage should be used to maintain therapeutic response. The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adult patients ...

CHARLOTTE, NC — People with moderate-to-severe ulcerative colitis benefit from stronger treatment from the start — a combination of monoclonal antibodies — compared with induction with either agent ...